Halah Z AlRawi

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Peritoneal Dialysis

Coronavirus Disease

Ejection Fraction

Top Venues

Pharmaceuticals (Basel, Switzerland)

Health science reports

This page only lists publications with an associated author ORCID identifier.

Publications

Halah Z AlRawi, Alaa Ashraf Bagader Alqurashi, Doaa AlDahan, Maha Alkhudhayri, Amani R Alsharidah, Tariq Wani, Dania AlJaroudi
Association between receiving Covid-19 vaccine and menstrual cycle patterns among childbearing women: A cross-sectional study. Health science reports 7 (5) (2024)
Halah Z AlRawi, Alaa Ashraf Bagader Alqurashi, Doaa AlDahan, Maha Alkhudhayri, Amani R Alsharidah, Tariq Wani, Dania AlJaroudi
Association between receiving Covid-19 vaccine and menstrual cycle patterns among childbearing women: A cross-sectional study. Health science reports 7 (5) (2024)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Bandar Alosaimi, Huda M Alshanbari, Muath Alturaiqy, Halah Z AlRawi, Saad Alamri, Asma Albujaidy, Aljawharah Bin Sabaan, Ahmed A Alrashed, Ahmed A Alamer, Fayez Alghofaili, Khaled Al-Duraymih, Abdulaziz J Alshalani, Wael Alturaiki
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)